Blindness drug developer Avalanche Biotechnologies Inc. boosted its IPO target to $93 million from $86 million, hoping to sell 6.2 million shares at $13 to $15 per share.
In addition, the Menlo Park gene therapy company will receive $10 million from partner and part-owner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from a private placement of stock, the company said in a Securities and Exchange Commission filing Monday.
Help employers find you! Check out all the jobs and post your resume.
